



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

#17

Food and Drug Administration
Rockville MD 20857

APR 15 1991

Re: Altace
Docket No. 91E-0136RECEIVED
APR 17 1991

RETS

Charles E. Van Horn, Esq.
Patent Policy and Projects Administrator
Office of the Assistant Commissioner for Patents
Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, D.C. 20231

Dear Mr. Van Horn:

This is in regard to the application for patent term extension for U.S. Patent No. 4,587,258 filed by Hoechst-Roussel Pharmaceuticals, Inc. under 35 U.S.C. 156. The human drug product claimed by the patent is Altace (ramipril), New Drug Application (NDA) 19-901.

A review of the Food and Drug Administration's official records confirms that Altace was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. 156(a)(4). Our records also indicate that NDA 19-901 represents the first permitted commercial marketing or use of the active ingredient, ramipril. The NDA was approved on January 28, 1991 which makes the submission of the patent term extension application on March 27, 1991 timely within 35 U.S.C. 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C 156(d)(2)(A), we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)

cc: Tatsuya Ikeda
Patent Department
Hoechst Celanese Corporation
P.O. Box 2500
Route #202-206 North
Somerville, New Jersey 08876-1258